Clinical trials
catalyst calendar across sponsors →Studies where ANVS is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
8 interventional · 4 with posted results
Held by 6 tracked-famous managers (MARSHALL WACE, LLP, RENAISSANCE TECHNOLOGIES LLC, TWO SIGMA INVESTMENTS, LP, CITADEL ADVISORS LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, +1 more) · FINRA short interest 9.4 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| An Open-label Long-term Safety Study of Buntanetap in Participants With ADNCT07757204Safety of buntanetapOpen-label · Treatment | Phase 2/3 | Not yet recruiting | Drug: buntanetap/posiphen | Alzheimer's Dementia (AD) | 400 | 2030-02-21 | in 1,281 d | 2026-08-19 |
| A Study of Buntanetap in Participants With PDNCT07284784Safety of buntanetapNon-randomized · Open-label · Treatment | Phase 2/3 | Recruiting | Drug: buntanetap/posiphen | Parkinson's Disease (PD), Deep Brain Stimulation | 500 | Sep 2029 | ≤ 1,137 d | 2026-07-21 |
| A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early ADNCT06709014Alzheimer's Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog13)Randomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: buntanetap/posiphen, Placebo | Early Alzheimers Disease | 760 | Dec 2027 | ≤ 498 d | 2026-05-18 |
| A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate ADNCT05686044results2025-04-29Change From Baseline to Week 12 in ADAS-Cog11Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2/3 | Completed | Drug: Buntanetap/Posiphen, Placebo | Alzheimer Disease | 351 | 2024-02-13actual | — | 2025-04-29 |
| A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PDNCT05357989results2025-03-03Change From Baseline to Month 6 in MDS-UPDRS Part II (OFF-state)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: buntanetap/posiphen, Placebo | Parkinson's Disease, Idiopathic | 523 | 2023-12-04actual | — | 2025-03-03 |
| Safety, Tolerability, PK and PD of Posiphen® in Subjects With Early Alzheimer's DiseaseNCT02925650results2023-05-09Safety and Tolerability of Multiple Ascending Doses of Posiphen: Reports of Adverse Events or Study DiscontinuationsRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ · Informed Consent Form ↗ | Phase 1/2 | Completed | Drug: Posiphen, Placebo | Alzheimer's Disease | 18 | 2021-12-10actual | — | 2023-05-09 |
| Posiphen® Dose-Finding, Biomarker Study in Early Alzheimer's and Parkinson's PatientsNCT04524351results2023-02-28Percentage of Participants With Treatment-Emergent Adverse EventsRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: Posiphen, Placebo | Alzheimer Disease, Parkinson Disease | 75 | 2021-08-16actual | — | 2023-02-28 |
| Study of the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Subjects With Amnestic Mild Cognitive ImpairmentNCT01072812PharmacokineticsOpen-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Business decision based on funding | Drug: Posiphen® tartrate capsules | Alzheimer's Disease, Amnestic Mild Cognitive Impairment | 5 | Jul 2010actual | — | 2015-04-22 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19